IN BRIEF: Hutchmed Elunate and Orpathys get expanded NRDL coverage
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its cancer drugs Elunate and Orpathys will receive expanded coverage under China's National Reimbursement Drug List from January 1, following a contract renewal with the National Healthcare Security Administration. Elunate gains coverage for treating advanced kidney cancer. Orpathys gains coverage for treating advanced lung cancer and is renewed for existing lung cancer treatment. Read More